SCHEMBL31661823

SCHEMBL31661823

Oc1ccccc1OCCCCCCCCN1CCOCC1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.65
ALDH1A1 P00352 4/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
TDP1 Q9NUW8 1/20 0.65
ABCB1 P08183 1/20 0.57
USP2 O75604 1/20 0.56
CYP2D6 P10635 3/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
TSHR P16473 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MEN1 O00255 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
KMT2A Q03164 1/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062605 1.00 KDM4E (0.65) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL4399410 1.00 KDM4E (0.65) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL31661824 1.00 KDM4E (0.65) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL13348914 1.00 KDM4E (0.65) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL4265430 0.99 KDM4E (0.63) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL17443426 0.94 KDM4E (0.69) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL5486254 0.91 KDM4E (0.63) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
SCHEMBL14396561 0.90 POLB (0.63) KDM4ESMN1; SMN2USP2TSHRPOLB
Citric Acid SCHEMBL5495834 0.85 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1
Citric Acid SCHEMBL1672548 0.85 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2TDP1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed